Key stats
About NEOVACS SA
Sector
Industry
CEO
Hugo Brugière
Website
Headquarters
Suresnes
Founded
1992
ISIN
FR0014010856
FIGI
BBG000WBN7R9
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The firm is developing a product portfolio using its Kinoid technology through self-antigens, which cause autoimmune or inflammatory diseases. Its product portfolio includes IFNa kinoid, IL-4/13 kinoid, and IgE kinoid. The company was founded by Daniel Zagury on April 16, 1993 and is headquartered in Paris, France.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange NEOVACS SA stocks are traded under the ticker A41BPL.
A41BPL stock is 11.11% volatile and has beta coefficient of 1.36. Track NEOVACS SA stock price on the chart and check out the list of the most volatile stocks — is NEOVACS SA there?
Today NEOVACS SA has the market capitalization of 857.93 K, it has increased by 89.90 K% over the last week.
No, A41BPL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, A41BPL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEOVACS SA stock right from TradingView charts — choose your broker and connect to your account.